peter hall says srx is a potential ten bagger, page-3

Ninie, significant deaths of patients is clearly a business risk for Sirtex. However, there are numerous factors working in their favour to suggest this is not really a threat.

1. Patients are screened for suitability, those which present significant risks are not accepted for treatment

2. In general, by the time liver cancer is identified, it is an uncurable condition. Sirtex offers a treatment which has many years of clinical trials to suggest that it offers a superior treatment over chemotherapy alone.

3. Track record - There have been a heck of a lot of clinical trials done on SIR Spheres. There have been deaths, but we are dealing with high risk, terminally ill patients, and I guess it is acceptable to have a few deaths. Nearly all medical procedures have risk of death due to complication.


Your second comment is ridiculous. There is 48 cents per share in cash alone. Equally, pheenom's comment is also more than a bit of silly dreaming.